Statins - efficacy and safety Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Sep 30, 2008
Keywords:
statins, safety, myopathy

Main Article Content

Marek Rosiak
I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego
Marek Postuła
1. I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego 2. Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej Warszawskiego Uniwersytetu Medycznego

Abstract

Statins are one of the greatest achievements of cardiological pharmacology in recent years. However, the withdrawal of cerivastatin in 2001 led to concern and much subsequent discussion over the safety of statins. This review looks at the evidence in relation to the benefits and risks of statins and demonstrates that the benefits of statins far outweigh the risks.

Downloads

Download data is not yet available.

Article Details

How to Cite
Rosiak , M., & Postuła , M. (2008). Statins - efficacy and safety. Cardiology in Practice, 2(3), 120-124. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1682
Issue
Vol 2 No 3 (2008)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Armitage J.: The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781-90.
2. LaRosa J.C., Grundy S., Kestelein J.J.P. et al.: Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets TNT Study). Am. J. Cardiol. 2007; 100: 747-752.
3. Josan K., Majumdar S.R., McAlister F.A.: The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008; 178(5): 576-584.
4. Newman C., Tsai J., Szarek M. et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14 236 patients. Am. J. Cardiol. 2006; 97: 61-67.
5. Angulo P.: Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
6. Karp I., Behlouli H., LeLorier J. et al.: Statins and Cancer Risk. Am. J. Med. 2008; 121: 302-309.
7. Fried L.F., Orchard T.J., Kasiske B.L.: Effect of lipid reduction on the progression of renal disease: a metaanalysis. Kidney Int. 2001; 59: 260-69.
8. Heart Protection Study Collaborative Group: N-terminal pro-B-type natriuetic peptide, vascular disease risk and cholesterol reduction in 20 536 patients in the MRC/BHF Heart Protections Study. J. Am. Coll. Cardiol. 2007; 49: 311-9.
9. Grabowski M., Filipiak K.J.: Simwastatyna – czy ma przewagę nad innymi statynami? Choroby Serca i Naczyń 2006; tom 3 (supl.A): A1-A4.